Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
63
TVTX Quote, Financials, Valuation and Earnings
Last price:
$27.9000
Seasonality move
:
2.05%
Day range:
$27.2500 - $31.4400
52-week range:
$12.9100 - $42.1300
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.37x
P/B ratio:
37.22x
Volume:
879.9K
Avg. volume:
2.6M
1-year change:
17.29%
Market cap:
$2.7B
Revenue:
$233.2M
EPS (TTM):
-$1.08
Analysts' Opinion
-
Consensus RatingTravere Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.3571, Travere Therapeutics, Inc. has an estimated upside of 38.42% from its current price of $27.8200.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.0000 representing 100% downside risk from its current price of $27.8200.
Fair Value
-
According to the consensus of 14 analysts, Travere Therapeutics, Inc. has 38.42% upside to fair value with a price target of $42.3571 per share.
TVTX vs. S&P 500
-
Over the past 5 trading days, Travere Therapeutics, Inc. has overperformed the S&P 500 by 5.35% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Travere Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Travere Therapeutics, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Travere Therapeutics, Inc. reported revenues of $164.9M.
Earnings Growth
-
Travere Therapeutics, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Travere Therapeutics, Inc. reported earnings per share of $0.25.
Enterprise value:
2.8B
EV / Invested capital:
--
Price / LTM sales:
6.37x
EV / EBIT:
--
EV / Revenue:
6.45x
PEG ratio (5yr expected):
-1.38x
EV / Free cash flow:
-26.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$370.8M
Return On Assets:
-16.15%
Net Income Margin (TTM):
-20.32%
Return On Equity:
-263.9%
Return On Invested Capital:
-21.07%
Operating Margin:
15.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $157M | $203.4M | $435.8M | $62.9M | $164.9M | |
| Gross Profit | $107.4M | $150.4M | $370.8M | $50M | $147.5M | |
| Operating Income | -$354.8M | -$279.7M | -$89.7M | -$56M | $24.9M | |
| EBITDA | -$313.5M | -$236.4M | -$35M | -$44.8M | $40.7M | |
| Diluted EPS | -$4.40 | -$4.56 | -$1.08 | -$0.70 | $0.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $579.1M | $534.8M | $686.2M | $324.7M | $371.1M | |
| Total Assets | $775.1M | $726.2M | $832.9M | $504.4M | $538.6M | |
| Current Liabilities | $113.2M | $131M | $139.4M | $190M | $135.1M | |
| Total Liabilities | $467.7M | $625.5M | $553.1M | $534.9M | $465M | |
| Total Equity | $307.4M | $100.7M | $279.8M | -$30.5M | $73.6M | |
| Total Debt | $256.2M | $403.4M | $400.7M | $397.1M | $324M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$264.2M | -$272.2M | -$58.6M | -$42.5M | $14.3M | |
| Cash From Investing | $36M | $162.7M | $52.4M | $46.1M | $86.6M | |
| Cash From Financing | $219.2M | $427K | $79M | $46K | -$65.3M | |
| Free Cash Flow | -$305.1M | -$304.4M | -$107.5M | -$50.7M | -$871K | |
TVTX
Sector
Market Cap
$2.7B
$24M
Price % of 52-Week High
72.63%
48.22%
Dividend Yield
0%
0%
Shareholder Yield
-6.33%
-1.63%
1-Year Price Total Return
31.9%
-22.68%
Beta (5-Year)
0.827
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$29.9863
200-day SMA
Buy
Level
$24.6692
Bollinger Bands (100)
Sell
Level
27.4437 - 35.9637
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$30.1208
Relative Strength Index (RSI14)
Sell
Level
36.2553
ADX Line
Sell
Level
25.1815
Williams %R
Neutral
Level
-59.8583
50-day SMA
Sell
Level
$33.2219
MACD (12, 26)
Buy
Level
7.9611
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Sell
Level
-5.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2961)
Sell
CA Score
(Annual)
Level (-3.4362)
Buy
Beneish M-Score
(Annual)
Level (-2.7109)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.9433)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, TVTX has received 12 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TVTX average analyst price target in the past 3 months is $42.3571.
-
Where Will Travere Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Travere Therapeutics, Inc. share price will rise to $42.3571 per share over the next 12 months.
-
What Do Analysts Say About Travere Therapeutics, Inc.?
Analysts are divided on their view about Travere Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Travere Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $31.0000.
-
What Is Travere Therapeutics, Inc.'s Price Target?
The price target for Travere Therapeutics, Inc. over the next 1-year time period is forecast to be $42.3571 according to 14 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TVTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Travere Therapeutics, Inc. is a Buy. 12 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TVTX?
You can purchase shares of Travere Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Travere Therapeutics, Inc. shares.
-
What Is The Travere Therapeutics, Inc. Share Price Today?
Travere Therapeutics, Inc. was last trading at $27.9000 per share. This represents the most recent stock quote for Travere Therapeutics, Inc.. Yesterday, Travere Therapeutics, Inc. closed at $27.8200 per share.
-
How To Buy Travere Therapeutics, Inc. Stock Online?
In order to purchase Travere Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TVTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TVTX
Sector
P/E ratio
--
23.16x
PEG ratio
-1.38x
-0.01x
P/B ratio
37.22x
1.73x
Price / LTM sales
6.37x
1.50x
Growth Metrics
TVTX
Sector
Revenue growth
162.11%
3.24%
Earnings growth
135.55%
11.06%
Revenue (5-year growth)
5.87%
6.28%
Earnings forecast
$0.37
-$0.19
Profitability
TVTX
Sector
Profitability FY 2024
$181.9M
$2.7M
Return on invested capital
-21.07%
-33.62%
Return on assets
-16.15%
-29.68%
Return on equity
-263.9%
-39.33%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Jan
29
Balance Sheet
TVTX
Sector
Total cash
$254.5M
$25.1M
Short term investments
$312.2M
$23.9M
Total assets
$594.1M
$72.8M
Long term debt
$324M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
91
SPHR alert for Feb 14
Sphere Entertainment Co. [SPHR] is down 0.2% over the past day.
Sell
39
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
